Last updated: August 19, 2026
Dofetilide is a mature, genericized antiarrhythmic used to maintain normal sinus rhythm in patients with atrial fibrillation or atrial flutter. Its market is clinically important but commercially modest. Revenue has shifted from branded Tikosyn to low-priced generic capsules, while inpatient initiation requirements, electrocardiographic monitoring, and torsades de pointes risk limit broad prescribing.
The product has no meaningful biologic or biosimilar exposure. Competitive pressure comes from generic manufacturers, alternative antiarrhythmics, catheter ablation, and newer atrial-fibrillation treatment pathways. Public companies generally do not report dofetilide revenue separately, making market-level financial estimates more reliable than company-specific sales figures.
What is dofetilide and how is it used?
Dofetilide is a Class III potassium-channel blocker that prolongs cardiac repolarization. The FDA approved it in 1999 under the brand name Tikosyn for conversion to normal sinus rhythm and maintenance of sinus rhythm in patients with atrial fibrillation or atrial flutter [1].
It is available as oral capsules in three strengths:
| Strength |
Typical label use |
| 125 mcg |
Reduced dose based on renal function or QT response |
| 250 mcg |
Common maintenance dose |
| 500 mcg |
Maximum standard dose in eligible patients |
Dosing is determined by creatinine clearance and QT interval. Treatment must be initiated or reinitiated in a hospital with continuous electrocardiographic monitoring for at least three days, or for at least 12 hours after conversion to normal sinus rhythm, whichever is longer [1].
This requirement has two commercial effects:
- It raises the cost and operational burden of starting therapy.
- It creates a barrier to rapid switching from competing products or outpatient initiation.
Dofetilide has an important clinical advantage over some alternatives because it can be used in patients with structural heart disease and reduced left ventricular function. The drug does not carry the same broad negative inotropic limitation as many other rhythm-control agents. Its main constraint is proarrhythmic risk, particularly QT prolongation and torsades de pointes.
What is the FDA regulatory status of dofetilide?
Dofetilide remains FDA-approved for maintenance of normal sinus rhythm in selected patients with atrial fibrillation or atrial flutter. Its label has not created a broad outpatient initiation pathway because the FDA-required monitoring protocol remains central to safe use [1].
FDA approval and exclusivity timeline
| Event |
Approximate date |
| FDA approval of Tikosyn |
October 1999 |
| Original branded product |
Pfizer |
| Small-molecule regulatory pathway |
NDA |
| Generic pathway |
ANDA |
| Current regulatory status |
Approved generic capsules and branded reference product history |
| Current U.S. exclusivity position |
No material new-drug exclusivity barrier |
The main commercial effect of FDA regulation is operational rather than exclusivity-based. Hospitals must maintain protocols for renal dosing, medication reconciliation, QT monitoring, and drug-interaction screening. These requirements favor institutions with established electrophysiology and pharmacy infrastructure.
What patents protect dofetilide?
Dofetilide’s principal U.S. patent protection was directed to the active pharmaceutical ingredient and related pharmaceutical use. The relevant primary patent commonly associated with the product is U.S. Patent No. 5,698,599, assigned to Pfizer-related entities and covering dofetilide compounds and uses.
Historical patent estate
| Patent or right |
Subject matter |
Commercial status |
| U.S. Patent No. 5,698,599 |
Dofetilide compound and related use claims |
Expired |
| Tikosyn NDA |
FDA approval for atrial fibrillation and atrial flutter |
No current exclusivity block |
| Capsule formulation protection |
Conventional oral capsule dosage form |
Weak or expired as a competitive barrier |
| Method-of-use protection |
Rhythm maintenance and conversion |
Historical protection; no meaningful current barrier |
| Pediatric exclusivity |
No major current commercial effect identified |
Expired or immaterial |
The core patent estate no longer protects a premium-priced product. Current competition is therefore based on manufacturing cost, supply reliability, wholesaler access, hospital formulary status, and regulatory compliance.
When did dofetilide lose exclusivity?
Dofetilide lost practical market exclusivity after expiration of the principal patent and the entry of approved generic versions. The branded product’s commercial protection has been inactive for many years.
The exact date relevant to a particular generic launch depends on patent-term adjustment, regulatory exclusivity, Paragraph IV litigation, and the approval history of the specific ANDA. The commercially important point is that generic competition is established and the market no longer supports branded exclusivity pricing.
Unlike products with active Orange Book patents, dofetilide does not have a current patent position that would support a credible delayed-generic strategy. The core active ingredient is old, the capsule formulation is conventional, and the product does not have a complex-device component.
What is the Orange Book status of dofetilide?
Dofetilide has historically been listed in the FDA Orange Book through the Tikosyn reference product. The relevant product is an oral capsule approved under Pfizer’s NDA.
The Orange Book is important for identifying the reference product, listed patents, and generic substitution pathway. For dofetilide, the current commercial conclusion is straightforward:
- The product is an established small-molecule reference drug.
- Generic applicants can use the ANDA pathway.
- No active Orange Book patent is likely to provide a durable market barrier.
- Paragraph IV risk is historical rather than a current source of market disruption.
- Generic entry has already reset price expectations.
Orange Book status should be checked against the latest FDA publication for transaction-level diligence because listed patents, delistings, and patent-term information can change.
How many patents cover dofetilide today?
The number of historically associated patents is higher than the number of patents with current blocking value. The main patent categories were:
- Active pharmaceutical ingredient claims.
- Therapeutic-use claims.
- Pharmaceutical composition claims.
- Manufacturing or process claims.
Most commercial protection has expired. Conventional capsules do not create a significant formulation moat. Dofetilide also lacks the delivery-system complexity seen in inhaled products, depot injections, transdermal systems, or drug-device combinations.
Are formulation patents a major risk?
Formulation patents are not a major current barrier for standard dofetilide capsules. The marketed dosage form is technically straightforward, and generic manufacturers can generally reproduce it using conventional capsule manufacturing, dissolution testing, stability studies, and bioequivalence documentation.
A new extended-release, fixed-dose combination, or modified-initiation product could create new intellectual-property value. Such a product would need to overcome clinical and regulatory challenges, including preservation of predictable exposure and control of QT prolongation.
Which companies compete in the dofetilide market?
The competitive field consists mainly of generic manufacturers and the branded reference-product owner. Generic availability has varied by supplier and strength over time.
Potential or historical suppliers have included large generic companies such as Teva, Mylan or Viatris, and other ANDA holders and contract manufacturers. Supplier participation can change because low-volume products are often discontinued, transferred, or placed on intermittent supply.
The market has two levels of competition:
Product-level competition
Generic dofetilide capsules compete on:
- Wholesale acquisition cost.
- Pharmacy and wholesaler availability.
- 125 mcg, 250 mcg, and 500 mcg supply.
- Packaging and bottle configurations.
- Manufacturing reliability.
- Hospital purchasing contracts.
Therapeutic competition
Dofetilide competes with:
- Amiodarone.
- Sotalol.
- Dronedarone.
- Flecainide.
- Propafenone.
- Catheter ablation.
- Rate-control treatment with beta blockers, calcium-channel blockers, or digoxin.
Amiodarone has broad efficacy but substantial long-term toxicity. Sotalol also creates QT and renal-monitoring concerns. Dronedarone has a more limited efficacy profile and important heart-failure restrictions. Flecainide and propafenone are generally unsuitable for patients with significant structural heart disease. These differences preserve a specialized role for dofetilide despite generic pricing.
What is the financial trajectory for dofetilide?
Dofetilide’s financial trajectory has four phases:
| Phase |
Market economics |
| Branded launch |
Premium pricing supported by FDA exclusivity and limited alternatives |
| Early adoption |
Hospital-based initiation restricted volume but supported specialist demand |
| Generic entry |
Rapid price compression and loss of branded share |
| Mature generic market |
Low unit economics, fragmented supply, stable niche demand |
Public financial disclosures generally do not provide a separate dofetilide revenue line. Pfizer historically reported Tikosyn within broader product portfolios rather than as a standalone segment. Generic manufacturers also typically aggregate sales within cardiovascular or legacy-products categories.
Revenue profile
The market’s revenue is likely concentrated in recurring maintenance therapy rather than treatment initiation. Each new patient requires a monitored hospital start, but the subsequent capsule therapy may continue for months or years. This creates a small installed base of chronic users with relatively predictable refill demand.
The commercial value per patient is low compared with branded cardiovascular drugs. A generic patient may generate only tens to low hundreds of dollars in annual drug spending, depending on dose, payer, dispensing channel, and acquisition price. Hospital initiation costs are materially higher than the drug acquisition cost and are captured primarily by providers rather than manufacturers.
Why generic revenue remains limited
Several factors constrain revenue:
- The eligible population is narrower than the total atrial-fibrillation population.
- Initiation requires hospitalization.
- Prescribers often favor amiodarone or ablation depending on patient characteristics.
- Generic price competition is intense.
- The product has no significant formulation premium.
- Supply interruptions can cause substitution or treatment discontinuation.
The market can remain clinically durable without producing material manufacturer revenue. This distinction is important for licensing and investment analysis.
What generic entry risks exist for dofetilide?
Generic entry risk is already realized rather than prospective. The main future risks relate to additional supplier entry, price erosion, and substitution.
Generic launch scenarios
| Scenario |
Likely outcome |
| Additional ANDA approval |
Lower prices and reduced supplier concentration |
| Existing supplier exit |
Temporary shortages and higher spot prices |
| Hospital contract change |
Rapid volume movement among generic suppliers |
| Reference-product withdrawal |
Generic substitution continues if an approved reference pathway remains |
| New formulation launch |
Limited premium opportunity unless clinical use materially improves |
A generic manufacturer can obtain commercial value from dofetilide only through scale, low-cost production, reliable supply, or portfolio bundling. Standalone marketing expenditure is difficult to justify.
Which companies are challenging dofetilide patents?
Historical Paragraph IV challenges likely accompanied generic entry, but current commercial competition is no longer defined by active patent litigation. Generic applicants using Paragraph IV certifications may have challenged the validity, enforceability, or infringement of listed patents before expiration.
The relevant litigation risk today is limited. Potential disputes would more likely involve:
- ANDA formulation differences.
- Manufacturing process claims.
- Labeling carve-outs.
- Supply contracts.
- Product liability.
- Shortage-related commercial disputes.
No active, high-value patent litigation comparable to disputes involving major oncology, immunology, or diabetes products is central to dofetilide’s present market.
How strong is the dofetilide patent estate?
The current patent estate is weak as a commercial exclusivity platform.
| Factor |
Assessment |
| Core compound patents |
Expired |
| New chemical entity exclusivity |
Expired |
| Formulation protection |
Limited |
| Method-of-use protection |
Historical and largely expired |
| Manufacturing barriers |
Moderate technical controls, low IP differentiation |
| Generic substitution risk |
High |
| Biosimilar risk |
None |
| Litigation leverage |
Low |
| Licensing value |
Limited unless tied to a new formulation or delivery technology |
Manufacturing is not effortless because dofetilide requires tight control of assay, impurities, content uniformity, and stability. Those requirements create execution risk, but they do not create a durable patent moat.
Does dofetilide face biosimilar competition?
No. Dofetilide is a chemically synthesized small molecule, not a biologic. It is subject to generic drug competition through the ANDA pathway rather than biosimilar competition under the Public Health Service Act.
The relevant regulatory standards are pharmaceutical equivalence and bioequivalence. Generic manufacturers must demonstrate that their products match the reference drug in strength, dosage form, route of administration, and performance under FDA requirements.
How does dofetilide compare with competing antiarrhythmics?
| Drug |
Main commercial position |
Key advantage |
Key limitation |
| Dofetilide |
Mature generic niche |
Usable in selected structural-heart-disease patients |
Mandatory inpatient initiation and QT risk |
| Amiodarone |
High-volume generic |
Broad efficacy |
Thyroid, pulmonary, hepatic, ocular, and neurologic toxicity |
| Sotalol |
Generic |
Familiar rhythm-control option |
QT risk, renal dosing, monitoring |
| Dronedarone |
Branded or limited generic economics |
Lower long-term toxicity than amiodarone |
Lower efficacy and heart-failure restrictions |
| Flecainide |
Generic |
Effective in selected patients without structural disease |
Contraindicated or unfavorable in structural heart disease |
| Propafenone |
Generic |
Rhythm-control option with oral formulations |
Drug interactions and structural-heart-disease limitations |
| Catheter ablation |
Procedure |
Can reduce recurrent atrial fibrillation and drug dependence |
Procedural cost, access, and patient-selection constraints |
Dofetilide’s strongest competitive position is clinical fit, not price or brand power. It remains relevant when clinicians want a rhythm-control drug that can be used in selected patients with heart failure or structural heart disease and are prepared to manage inpatient initiation.
What licensing deals affect dofetilide?
No major current licensing transaction is central to dofetilide’s market. The commercial pathway is dominated by internal generic development, ANDA ownership, contract manufacturing, and distribution agreements.
Potential transaction value is more likely to arise from:
- Acquisition of an approved ANDA.
- Transfer of manufacturing rights.
- Portfolio acquisition of mature cardiovascular products.
- Supply agreements with hospitals or wholesalers.
- Licensing of a new modified-release formulation.
A deal based only on the legacy dofetilide capsule would face low pricing, limited differentiation, and modest market growth. A transaction involving improved initiation logistics, an alternative delivery system, or a clinically differentiated formulation would have a stronger strategic rationale.
What revenue exposure do manufacturers have?
For large generic companies, dofetilide revenue exposure is likely immaterial relative to total sales. For a smaller specialty or generic manufacturer, the product can be strategically useful because it may provide:
- Recurring chronic-care demand.
- A specialized hospital-prescribing niche.
- Portfolio depth in cardiovascular products.
- Cross-selling opportunities with pharmacy and hospital accounts.
The main financial risks are low annual revenue per patient, limited volume growth, and manufacturing economics that deteriorate when several suppliers compete for the same demand.
Key Takeaways
- Dofetilide is an FDA-approved Class III antiarrhythmic for atrial fibrillation and atrial flutter.
- Tikosyn’s core patent and exclusivity position is historical; generic competition is established.
- The current market is driven by hospital initiation protocols, generic supply, and clinical specialization.
- Dofetilide has no biosimilar risk because it is a small-molecule drug.
- Formulation and method-of-use patents do not create a material current barrier for standard capsules.
- Public companies do not generally disclose dofetilide sales separately.
- The market offers stable niche demand but limited standalone growth or licensing value.
- The strongest commercial risks are price erosion, supplier exits, shortages, and therapeutic substitution.
- The strongest clinical differentiator is use in selected patients with structural heart disease or reduced ejection fraction.
- A commercially attractive new product would need a meaningful formulation, delivery, or treatment-setting advantage.
FAQs
Is dofetilide still commercially available?
Yes. Dofetilide remains available as an FDA-approved oral capsule through generic suppliers, although availability can vary by strength, wholesaler, and manufacturer.
Can dofetilide be started at home?
No. FDA labeling requires inpatient initiation or reinitiation with continuous ECG monitoring and renal-function-based dosing.
Is Tikosyn more profitable than generic dofetilide?
Historically, Tikosyn had higher unit economics because it was branded. In the mature market, generic dofetilide has much lower pricing and no meaningful premium unless supply is constrained.
Can a new company obtain market exclusivity for a dofetilide formulation?
Potentially, but a new formulation would need patentable technical features and separate FDA approval. Commercial value would depend on improved safety, adherence, initiation logistics, or a clearly differentiated clinical use.
Is dofetilide a growth product for pharmaceutical investors?
No. It is better classified as a mature, low-growth generic cardiovascular product. Investment value depends on manufacturing efficiency, portfolio scale, supply reliability, and acquisition price rather than market expansion.
References
- U.S. Food and Drug Administration. (2023). Tikosyn (dofetilide) prescribing information. Pfizer Laboratories.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (1999). FDA approves Tikosyn for atrial fibrillation and atrial flutter.
- Pfizer Inc. (Various years). Annual reports and Form 10-K filings.
- January, C. T., Wann, L. S., Calkins, H., et al. (2019). 2019 AHA/ACC/HRS focused update of the 2014 guideline for the management of patients with atrial fibrillation. Circulation, 140(6), e285-e292.
